Liver Cirrhosis - Pipeline Review, H1 2017

Description: Liver Cirrhosis - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Liver Cirrhosis - Pipeline Review, H1 2017, provides an overview of the Liver Cirrhosis (Gastrointestinal) pipeline landscape.

Cirrhosis is scarring of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcohol abuse. The scar tissue damages the normal structure of the liver which affects the normal flow of blood through the liver. Symptoms include loss of appetite, itchy skin, weight loss, tiredness and weakness and nausea. Treatment includes liver transplant surgery.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Liver Cirrhosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Liver Cirrhosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Liver Cirrhosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Liver Cirrhosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 3, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Liver Cirrhosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Cirrhosis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Liver Cirrhosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Liver Cirrhosis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Liver Cirrhosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Liver Cirrhosis (Gastrointestinal).
Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Liver Cirrhosis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Liver Cirrhosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents:

Introduction
Liver Cirrhosis - Overview
Liver Cirrhosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Liver Cirrhosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Liver Cirrhosis - Companies Involved in Therapeutics Development
Conatus Pharmaceuticals Inc
Galectin Therapeutics Inc
Gilead Sciences Inc
Human Stem Cells Institute
International Stem Cell Corp
Ocera Therapeutics Inc
Pharmicell Co Ltd
Liver Cirrhosis - Drug Profiles

BCD-800 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

Cell Therapy for Liver Cirrhosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

Cellgram-LC - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

emricasan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

Gemacell - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

GMCT-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

GRMD-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GXHPC-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ND-654 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ornithine phenylacetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit NLRP3 for Liver Cirrhosis and Non-Alcoholic Steatohepatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Alpha-Antitrypsin Deficiency, Crigler-Najjar Syndrome and Liver Cirrhosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Articular Cartilage Defect, Cerebral Hemorrhage, Liver Cirrhosis, Pneumoconiosis and Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Liver Cirrhosis and Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Liver Cirrhosis and Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Liver Fibrosis and Liver Cirrhosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Metabolic, Gastrointestinal, Multiple Organ Failure and Respiratory Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stempeucel - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STNM-04 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Liver Cirrhosis - Dormant Projects
Liver Cirrhosis - Discontinued Products
Liver Cirrhosis - Product Development Milestones
Featured News & Press Releases
Nov 14, 2016: Conatus Announces Poster Presentations at AASLD Annual Meeting
Nov 03, 2016: Conatus Initiates Phase 2b ENCORE-PH Clinical Trial of Emricasan in Patients with NASH Cirrhosis
May 04, 2016: Conatus Extends Positive Results with Emricasan in Phase 2 Liver Cirrhosis Clinical Trial
Apr 18, 2016: Conatus Late Breaker Oral Presentation at EASL Details Phase 2 Liver Cirrhosis Trial Three-month Data
Mar 30, 2016: Conatus Pharmaceuticals Announces Late Breaker Oral Presentation on Emricasan at EASL Meeting
Jan 05, 2016: Conatus Achieves Positive Results with Emricasan in Initial Stage of Phase 2 Liver Cirrhosis Clinical Trial
Nov 16, 2015: Conatus Pharmaceuticals Announces Late-Breaking Oral Presentation at AASLD Annual Meeting
Nov 16, 2015: Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting
Oct 20, 2015: Conatus Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for AASLD Annual Meeting
Oct 01, 2015: Conatus Pharmaceuticals Announces Acceptance of Abstracts for AASLD Annual Meeting
Jun 25, 2015: Conatus Announces Initial Baseline Data From Phase 2b POLT-HCV-SVR Clinical Trial of Emricasan Confirming Activity of Relevant Mechanisms and Opportunity for Histological Improvement

May 14, 2015: Galectin Therapeutics Reports no Drug-Drug Interaction Between GR-MD-02 and Midazolam

Nov 10, 2014: Conatus Pharmaceuticals Presents Late-Breaking Poster At AASLD Annual Meeting

Oct 08, 2014: Conatus Pharmaceuticals Announces Acceptance Of Late-Breaking Abstract For AASLD Annual Meeting

Sep 02, 2014: Conatus Pharmaceuticals Initiates Phase 2 Trial in Patients with Liver Cirrhosis and Separate Open Label Phase 2 Trial in Cirrhosis Patients with Portal Hypertension

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Liver Cirrhosis, H1
Number of Products under Development by Companies, H1
Number of Products under Development by Universities/Institutes, H1
Products under Development by Companies, H1
Products under Development by Universities/Institutes, H1
Number of Products by Stage and Target, H1
Number of Products by Stage and Mechanism of Action, H1
Number of Products by Stage and Route of Administration, H1
Number of Products by Stage and Molecule Type, H1
Liver Cirrhosis - Pipeline by Conatus Pharmaceuticals Inc, H1
Liver Cirrhosis - Pipeline by Galectin Therapeutics Inc, H1
Liver Cirrhosis - Pipeline by Gilead Sciences Inc, H1
Liver Cirrhosis - Pipeline by Human Stem Cells Institute, H1
Liver Cirrhosis - Pipeline by International Stem Cell Corp, H1
Liver Cirrhosis - Pipeline by Ocera Therapeutics Inc, H1
Liver Cirrhosis - Pipeline by Pharmicell Co Ltd, H1
Liver Cirrhosis - Pipeline by S-Evans Biosciences Inc, H1
Liver Cirrhosis - Pipeline by Stelic Institute & Co Inc, H1
Liver Cirrhosis - Pipeline by Stempeutics Research Pvt Ltd, H1
Liver Cirrhosis - Pipeline by VESSL Therapeutics Ltd, H1
Liver Cirrhosis - Dormant Projects, H1
Liver Cirrhosis - Discontinued Products, H1

List of Figures:

Number of Products under Development for Liver Cirrhosis, H1
Number of Products under Development by Companies, H1
Number of Products under Development by Universities/Institutes, H1
Number of Products by Top 10 Targets, H1
Number of Products by Stage and Top 10 Targets, H1
Number of Products by Top 10 Mechanism of Actions, H1
Number of Products by Stage and Top 10 Mechanism of Actions, H1
Number of Products by Routes of Administration, H1
Number of Products by Stage and Routes of Administration, H1
Number of Products by Molecule Types, H1
Number of Products by Stage and Molecule Types, H1

Ordering:

Order Online - http://www.researchandmarkets.com/reports/4143202/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

- Product Name: Liver Cirrhosis - Pipeline Review, H1 2017
- Web Address: http://www.researchandmarkets.com/reports/4143202/
- Office Code: SC

Product Formats
Please select the product formats and quantity you require:

- Electronic (PDF) - Single User: USD 2000
- Electronic (PDF) - Site License: USD 4000
- Electronic (PDF) - Enterprisewide: USD 6000

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in **BLOCK CAPITALS**

- Title:  
  - Mr  
  - Mrs  
  - Dr  
  - Miss  
  - Ms  
  - Prof

- First Name: ____________________________  
- Last Name: ____________________________

- Email Address: * ____________________________

- Job Title: ____________________________

- Organisation: ____________________________

- Address: ____________________________

- City: ____________________________

- Postal / Zip Code: ____________________________

- Country: ____________________________

- Phone Number: ____________________________

- Fax Number: ____________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World